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ABSTRACT OF THESIS 
 
 
 
 
RELATIONSHIPS OF LONG-TERM BISPHOSPHONATE TREATMENT WITH 
MEASURES OF BONE MICROARCHITECTURE AND MECHANICAL 
COMPETENCE 
 
 
Oral bisphosphonate drug therapy is a common and effective treatment for 
osteoporosis. Little is known about the long-term effects of bisphosphonates on bone 
quality. This study examined the structural and mechanical properties of trabecular bone 
following 0-16 years of bisphosphonate treatment. Fifty-three iliac crest bone samples of 
Caucasian women diagnosed with low turnover osteoporosis were identified from the 
Kentucky Bone Registry. Forty-five were treated with oral bisphosphonates for 1 to 16 
years while eight were treatment naive. A section of trabecular bone was chosen from a 
micro-computed tomography (Scanco µCT 40) scan of each sample for a uniaxial linearly 
elastic compression simulation using finite element analysis (ANSYS 14.0). Morphometric 
parameters (BV/TV, SMI, Tb.Sp., etc.) were computed using µCT.  Apparent modulus, 
effective modulus and estimated failure stress were calculated. Biomechanical and 
morphometric parameters improved with treatment duration, peaked around 7 years, and 
then declined independently of age. The findings suggest a limit to the benefits associated 
with bisphosphonate treatment and that extended continuous bisphosphonate treatment 
does not continue to improve bone quality. Bone quality, and subsequently bone strength, 
may eventually regress to a state poorer than at the onset of treatment. Treatment duration 
limited to less than 7 years is recommended. 
 
KEYWORDS: bisphosphonates, bone microarchitecture, finite element analysis, micro-
computed tomography, osteoporosis 
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Introduction 
 
  The primary purpose of bone is to act as a storage site for calcium as part of the 
overall regulation of plasma calcium in the human body. Structural support follows as a 
secondary purpose. This dual purpose is reflected in the hierarchical structure of bone. At 
the nanoscale level, all bone consists of mineralized collagen fibrils. The fibrils consist of 
an organic matrix (30% of volume), which is 90% type I collagen, and mineral 
nanoparticles made of carbonated hydroxyapatite (70% of volume) [1]. The organization 
at scales above this depends on the type of bone. At the macroscale level, bone is 
classified into two types, cortical and cancellous bone (Figure 1). Cortical bone is dense, 
accounting for approximately 80% of the skeleton’s bone mass and contributes mainly to 
the loadbearing structural purpose of bone. The collagen fibrils are arranged into larger 
fibers that make up units called osteons in cortical bone at the microscale level. These 
units are called trabeculae in cancellous bone. In contrast to cortical bone, cancellous 
bone, also known as “spongy bone” or “trabecular bone”, is a porous structure of rods 
and plates and contributes 10 times as much surface area as cortical bone does [2]. The 
increased surface area allows trabecular bone to be the primary interface for calcium 
storage and regulation with the rest of the body. 
 
Ninety-nine percent of the body’s calcium, 85% of the phosphate, and 50% of the 
magnesium are stored in bone [2]. The storage of these minerals contributes to 
accomplishing both bone’s primary purpose of calcium homeostasis as well as the 
secondary purpose of structural support. The mineral content increases the rigidity and 
brittleness of the bone [3, 4]. Thus, variations in the tissue of bone at the nanoscale level 
change the material properties which contribute to overall mechanic response of bone to 
loading. 
 
Variations in the macroscale and microscale structure of bone greatly influence 
the biomechanics of bone and are an important factor governing bone quality as well. As 
previously noted, much of the structural support of bone is contributed by cortical bone; 
however, the trabecular network also plays a vital role in distributing loads between 
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sections of cortical bone or articulating surfaces [5]. The trabecular network is able to 
optimize the transmission of loads through changes in key structural parameters. For 
example, the trabecular struts could change in number, thickness, or shape becoming 
more plate-like instead of rod-like. Additionally, the fibers forming the osteons or 
trabeculae are arranged along stress lines so that the bone is more capable of bearing 
loads in the direction at which those loads are normally experienced [2]. The adaptation 
of bone structure in response to changes in mechanical loading is a principle known as 
Wolff’s Law.  
 
Adaptations in accordance with Wolff’s Law are achieved through bone turnover. 
Bone turnover is the process by which bone constantly remodels and repairs its structure. 
Resorption is the first step of bone turnover and is executed by large multinucleated cells 
called osteoclasts. Osteoclasts work in the shape of a cutting cone secreting hydrogen 
ions to dissolve the mineral crystals and hydrolytic enzymes to digest the osteoid matrix. 
The osteoclasts have a linear resorption rate of approximately 50 microns per day [6]. In 
the next step, bone formation, cells called osteoblasts lay the foundation for new bone by 
creating the bone collagen matrix. Once the matrix is laid, the bone can undergo 
mineralization, and calcium is stored. At only approximately 1 micron per day, the linear 
rate of bone formation is not nearly as fast as the resorption [6]. 
 
 In normal healthy adults, bone resorption and formation are balanced so that there 
is no net change in bone mass during the remodeling process. Occasionally, an imbalance 
in favor of formation will cause a net increase in bone mass such as during human 
development [7]. Conversely, the disease osteoporosis is characterized by an imbalance 
between resorption and formation causing a net decrease in bone mass. As a result, the 
structural integrity of the skeletal system is compromised predisposing the bone to 
fracture. The majority of these fractures occur at the hip, spine, or forearm. Osteoporotic 
fractures often lead to a decrease in quality of life for the patient, and fractures of the hip 
and spine are strongly associated with high mortality within the 2 years following the 
fracture[8-10]. The World Health Organization (WHO) defines osteoporosis as a bone 
mineral density (BMD) measurement 2.5 standard deviations or more below the mean 
3 
 
[11]. BMD assessment by dual x-ray absorptiometry (DXA) is the current gold standard 
for diagnosis [12]. New diagnostic tools such as fracture-risk assessment (FRAX) have 
been added to the diagnosis process because osteoporosis is a disease of low bone 
strength and not just low bone mass [13, 14]. 
 
Unfortunately, osteoporosis is the most prevalent metabolic bone disease in the 
world and is considered an epidemic in most developed countries [15, 16]. According to 
the National Osteoporosis Foundation, about 54 million Americans have osteoporosis 
[17]. Although osteoporosis has been observed in all populations, the disease is most 
prevalent in women [18]. Natural bone loss with age and decreases in estrogen levels 
increase the risk of developing osteoporosis. Postmenopausal Caucasian women, 
therefore, are one of the most at risk populations. Studies report the lifetime risk of 
fracture, including but not limited to those linked to osteoporosis, for Caucasian women 
over the age of 50 to be between 40-47.3% [19-21]. These fractures generate a significant 
socioeconomic burden. In 1990, the worldwide direct and indirect annual cost of hip 
fractures was estimated to be $35 billion [22]. By 2005, the cost of osteoporotic fractures 
in the United States alone had reached an estimated $19 billion [1]. This number is 
expected to continue to increase to $25.3 billion by 2025 [17]. 
 
Lifestyle modifications such as increased weight-bearing exercise and smoking 
cessation along with calcium and vitamin D supplementation are recommended as a 
baseline treatment. In addition, drug therapies are often necessary to treat osteoporosis 
[19]. Efforts to combat the turnover imbalance associated with osteoporosis fall into two 
classes, anabolic and antiresorptive therapies. Two osteoanabolic drugs, parathyroid 
hormone (PTH) and teriparatide, are currently available. These drugs increase bone 
formation by targeting the signaling pathways to the osteoclasts and osteoblasts [23]. 
Denosumab, an antiresorptive, targets the signaling pathway to osteoclasts leading to 
reduced bone resorption [23]. 
 
Currently, bisphosphonates are the oldest and most popular of the antiresorptive 
drugs approved for the treatment of osteoporosis. The primary mechanism of action is the 
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reduction of turnover by binding to bone hydroxyapatite and inducing apoptosis of 
osteoclasts [24] (Figure 2).  Bone turnover has been shown to decrease up to 90% with 
bisphosphonates [25]. As the age of the bone tissue increases, BMD and mineral 
homogeneity also increase. Ultimately, this leads to an increased resistance to fracture. 
Numerous studies have documented a reduced risk of osteoporotic fractures associated 
with bisphosphonates [26-29].  
 
Understanding how bisphosphonates help prevent fracture involves studying how 
osteoporosis and bisphosphonates alter all aspects of bone quality. In addition to 
mineralization and turnover, bone quality encompasses bone architecture, geometry, 
tissue properties, and microdamage (Figure 3). Each of these factors can be evaluated 
using a variety of tests and tools [30]. Infrared spectroscopy was used to show that 3 
years of bisphosphonate treatment was associated with increased mineral content while 
having no significant effect on other tissue properties such as crystallinity or collagen 
maturity [31]. Microdamage in dogs was found to increase with 3 years of 
bisphosphonate treatment, but the microdamage was not significantly greater than the 
levels found after 1 year of treatment [32]. Several studies have documented the 
preservation of bone microarchitecture through 3 years of bisphosphonate treatment using 
various imaging technologies [33-37].  
 
While the benefits of bisphosphonates for bone strength in the short-term are well 
documented and undisputed, evidence that these benefits continue with long-term 
treatment is sparse. It has been shown that gains in BMD and a drop in bone turnover rate 
over the first 5 years of treatment are preserved through 10 years of treatment [38]. BMD 
and bone turnover measures, however, do not completely explain bone mechanical 
competency. Furthermore, concerns have arisen over atypical fractures of the femur 
observed in patients undergoing long-term bisphosphonate therapy [39, 40]. The exact 
cause of these fractures has yet to be determined. Such concerns associated with long-
term bisphosphonate treatment have caused some to suggest that a “drug holiday” may be 
necessary, and consideration is growing for a stoppage in bisphosphonate treatment after 
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3-5 years [41, 42]. More evidence is required before any official recommendations can be 
made.  
 
Recent improvements in imaging technology have allowed for greater clarity in 
the examination of bone microarchitecture. Peripheral quantitative computed tomography 
(pQCT) has been used in the clinical setting to assess bone density and architecture. 
Typical resolutions are in the range of ~80 to 100 µm. It has been suggested, however, 
that scans at this range of resolution may not provide reliable structural detail [43]. 
Micro-computed tomography (µCT; microCT) is able to capture 3D images with a 
resolution as low as 8 µm. These high resolution scans of bone biopsies allow for both a 
visual and quantitative assessment of trabecular microarchitecture. Studies have 
confirmed the ability of microCT to provide 3D morphometric data with accuracy and in 
less time than conventional histomorphometry [44-46]. 
 
Overall bone mechanics can be analyzed through mechanical testing such as a 
uniaxial compression test of a trabecular bone segment. By physically loading an actual 
segment of bone, the test accounts for nearly all the factors contributing to bone’s 
resistance to fracture intrinsic to the bone segment, but a biopsy is required and will be 
destroyed in the process. As an alternative, finite element analysis (FEA) is an 
engineering tool initially developed for the aerospace industry that is capable of 
simulating mechanical testing. The method consists of discretizing the object of study 
into a finite number of pieces or elements. Relevant material properties are assigned to 
the elements, and desired boundary conditions such as a force or displacement are 
applied. Equations of static or dynamic equilibrium associated with each element are 
computed until a solution is reached for the unknown variables.  
 
FEA provides a visualization of bone’s mechanical competency and insight into 
the contribution of bone material properties and architecture. Initially, FEA studies of 
trabecular bone analyzed idealized models consisting of a combination of plates and 
beams meant to mimic trabecular geometry [47]. As with any simulation, FEA is only as 
accurate as the input for the simulation. The introduction of 3D digital reconstructions of 
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bone segments allowed for accurate representation of actual bone architecture in finite 
element models [5]. The methods for converting image-based models into FEA meshes 
and for applying boundary conditions continue to be refined in order to ensure that the 
mechanical analyses accurately represent the state of the bone [48-50].  
 
The behavior of trabecular bone in the elastic region has been shown to fit a linear 
model [51]. The slope of the linear relationship between load force and displacement in 
this region is the bone’s stiffness. Similarly, the slope of the linear relationship between 
stress and strain is the bone’s Young’s modulus of elasticity which is a measure of 
rigidity. Mechanical properties of trabecular bone in the elastic region such as stiffness 
and Young’s modulus of elasticity have been shown to be strong predictors of bone 
strength [52, 53]. Many FEA studies of trabecular bone segments, therefore, conduct a 
linear analysis to assess overall bone strength [37, 48, 54, 55]. Methods for capturing the 
nonlinear behavior in the plastic region of deformation continue to be developed and 
refined [56]. Numerous studies have verified that FEA can accurately reproduce the 
results of mechanical tests where a bone segment is physically crushed [48, 53, 54, 56]. 
The evolution of FEA in the study of trabecular bone mechanics and the current state of 
the art have recently been detailed [57]. 
 
Previous studies have raised questions and concerns over the efficacy of long-
term use of the commonly prescribed bisphosphonates. Currently, few studies examining 
the effects of bisphosphonates on bone quantity and quality extend beyond 5 years of 
treatment. Furthermore, studies spanning a longer treatment duration focus primarily on 
just bone quantity. To broaden the understanding on this subject, this study aimed to 1) 
quantify the relationship of bisphosphonate treatment of varying durations with the 
mechanical competency of bone and 2) to assess the relationships between microCT-
derived structural indices and FEA-derived biomechanical measures. Consequently, this 
study tested the hypothesis that there is a relationship between long-term bisphosphonate 
treatment and measures of bone mechanics and bone microarchitecture. 
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Figure 1. Cortical and trabecular bone. 
Figure 2. Proposed bisphosphonate mechanism of action. Reproduced with 
permission from Solomon, CG. Bisphosphonates and osteoporosis. N Engl J 
Med.2002, 346:642., Copyright Massachusetts Medical Society. 
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Figure 3. Factors determining the quality and fracture resistance of bone. 
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Methods 
 
Study Design 
This computer-based study examined trabecular bone from postmenopausal 
women diagnosed with osteoporosis to determine the relationships among 
bisphosphonate treatment of widely varying (0-16 years) duration, microarchitecture and 
mechanical properties. Analysis was limited to trabecular bone as the technique used to 
procure the biopsies did not consistently provide a segment of cortical bone suitable for 
study. Power calculations of a previous study [58] indicated that a sample size of 50 
spread evenly over 15 years of treatment along with 10 untreated specimens was required 
to detect a change in strength with treatment duration (power = 0.95, α = 0.05).  
Structural indices to be measured from microCT-based 3D morphometry 
included:  
1. bone volume fraction (BV/TV)  
2. structure model index (SMI) 
3. connectivity density (CD) 
4. trabecular separation (Tb.Sp.) 
5. trabecular thickness (Tb.Th.) 
Biomechanical properties to be calculated from linearly elastic FEA included:  
1. apparent modulus (Eapp) 
2. effective modulus (Eeff) 
3. estimated failure stress (Pfail)  
 
Bone Sample Procurement 
Much of the focus of the FEA study of human trabecular bone has been conducted 
using bone from the vertebrae of cadavers. The Kentucky Bone Registry’s vast database 
of bone biopsies obtained from the iliac crest offered an opportunity for an unprecedented 
study of bone from living subjects with varying durations of bisphosphonate treatment. 
Approximately 8,000 biopsies have been collected in the available database. All biopsies 
were obtained for diagnostic purposes by sterile, minimally invasive surgical procedures 
performed at the University of Kentucky Medical Center. All bone biopsies were 
extracted by drilling into the superior surface of the subject’s anterior iliac crest. The 
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resulting cores were either 3 mm or 4 mm in diameter. Cores were then “fixed with 
ethanol at room temperature, dehydrated, and embedded in methylmethacrylate” [59] 
(Figure 4).  
 
Subject Inclusion Criteria 
Alendronate (Fosamax) became the first bisphosphonate to receive FDA approval 
for the treatment of osteoporosis in September 1995. The other two oral bisphosphonates 
included in the present study, risedronate (Actonel) and ibandronate (Boniva), were 
approved in 1999 and 2003, respectively. For this reason, no biopsies obtained prior to 
1995 were included in the present study. Furthermore, due to improvements in the 
available clinical notes starting in 1998, only the 1649 biopsies extracted from 1998 to 
2013 were of interest (Figure 5). Biopsies were selected from this subset according to 
strict criteria based on the subject’s medical history. Based on the corresponding clinic 
notes, 434 biopsies were from Caucasian female subjects at least 35 years of age who 
were diagnosed with low turnover osteoporosis (Figure 5). Low bone turnover was 
diagnosed by qualitative assessment of the biopsy histology slide. Since bisphosphonates 
are known to suppress turnover, the presence of high turnover would suggest an abnormal 
response or a compliance issue with the prescribed drug regimen. Hence, biopsies that 
displayed high turnover were more likely to be associated with poor compliance.  
 
Subject Exclusion Criteria 
Subjects were excluded if the clinic notes indicated prior treatment with long-term 
steroids, anticonvulsants found to influence bone loss (e.g. phenobarbital), or other 
osteoporosis drug therapies (e.g. teriparatide or denosumab).  Diagnosis of other bone 
diseases (e.g. Paget’s disease or Osteogenesis imperfecta) and any other abnormal 
conditions (e.g. recent cancer or paraplegia) were also a cause for exclusion. After all 
medical exclusion criteria were applied, 211 subjects remained (Figure 5). 
 
Biopsies from these subjects were then checked for poor biopsy quality. To assess 
overall quality, biopsies which met the medical criteria were initially examined under a 
microscope (Leica StereoZoom, Leica Microsystems, Heerbrugg, Switzerland) at 2.5x 
magnification for physical criteria. An eligible biopsy for study must have demonstrated 
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at least a 4mm long straight segment of trabecular bone free from the influence of cortical 
bone. Ideally, the biopsies would be at least 3-5mm in diameter or, more specifically, 
spanning at least 5 intratrabecular lengths in each direction to satisfy the continuum 
assumption [60].  The continuum assumption means that the bone segment can be 
assumed to be an accurate representation of the state of bone throughout the body. 
Unfortunately, this would be far too limiting for the study as all biopsies were extracted 
as nominally 4-mm diameter cores (prior to 2006) or 3-mm diameter cores (2006-
Present).  
Preferably, the embedded biopsy would be obtained for analysis prior to cutting 
for histology. If the biopsy had been cut, the depth of the biopsy perpendicular to the 
cutting plane was measured with a digital micrometer (Marathon, Richmond Hill, 
Canada; resolution: 0.001mm, accuracy: 0.002mm). This depth measurement was an 
estimate due to the imprecision associated with measuring an embedded biopsy (Figure 
6). Biopsies with an estimated depth reduced to under 2.000 mm were immediately 
excluded. After this initial check of biopsy quality, biopsies from 97 subjects remained 
eligible (Figure 5). 
 
MicroCT Scanning 
Biopsies that met both the medical history and the physical quality criteria were 
enrolled in the study. Analysis of these samples began by scanning each biopsy using a 
Scanco µCT40 (Scanco AG, Zurich, Switzerland) to obtain a digital reproduction of the 
bone. Briefly, microtomography works by means of a source and a detector on either side 
of the tested object. A small tube that emits a fan-beam of x-rays at a small angle acts as 
the source and a linear CCD-array acts as the detector. As the x-ray beam penetrates the 
object, the denser the material is, the more radiation is absorbed. Before reaching the 
CCD-array, the x-rays are transformed into visible light by a scintillator. This process of 
acquiring absorption information is repeated as the object is rotated 180° while the source 
and detector remain fixed. The data collected at each projection along the rotation is 
compiled into a sinogram which plots the data using coordinates of the projection angle 
and the distance along the projection [61]. The image is reconstructed by means of a 
standard convolution procedure [62]. The result is a single 2D slice of the object. In order 
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to obtain a 3D image, the whole process is repeated moving in specified increments along 
the object’s axis of rotation until the desired number of slices is acquired. 
   
Scanning Procedure 
The scanning procedure started with the creation of an appropriate control file. 
All biopsies were scanned using the same control file settings of 70 kV energy, 114 µA 
intensity, 500 projections per 180°, and 30 µm voxel size. The voxel size was dictated by 
the number of projections and the 30.7-mm field of view; this was the minimum size 
required to capture the full diameter of the tube used to hold the biopsy. A 0.5-mm 
aluminum filter was also applied to reduce the effect of beam hardening which would 
reduce the quality of the segmentation [63]. Scanco provided holders in various sizes, and 
the 30-mm diameter tube was the smallest that could hold the PMMA cylinders in which 
the biopsies were embedded. Once the control file was created, a single biopsy was 
packed tightly into its holder with foam, and securely placed in the scanner. Any motion 
of the biopsy other than the controlled rotation could significantly reduce the quality of 
the scan.  
 
A scout scan was completed for each biopsy yielding a preview image which was 
used to identify the number of slices necessary to capture the entire biopsy. More slices 
equated to a longer scan time. Therefore, the minimum number of slices required to 
capture the entire biopsy was desired. This number varied with each biopsy and depended 
on both the size of the biopsy and the angle at which it was embedded in the PMMA 
cylinder. Generally, the number of slices was between 70-150 slices which corresponded 
to a scanning time of 9-20 minutes per biopsy with roughly the same amount of time 
required for image reconstruction. The scout view also provided a more accurate 
measurement of the depth of the biopsy, thus samples could drop out at this stage if this 
value was deemed less than 2.05 mm. Upon selection of the number of slices, the full 
scan commenced. 
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2D Inspection 
Once scanning finished, the biopsy was opened for 2D analysis where each slice 
of the scan could be analyzed (Figure 7). In these images, the differences between 
cortical and trabecular bone were more distinct. Thus, this step also served as a second 
check of the quality inspection previously completed with the microscope. Each slice was 
coarsely contoured to define the volume of interest for the creation of a 3D segment. At 
this stage, the volume of interest included the entire biopsy.  
 
3D Segmentation 
A 3D segment was created after the voxels describing bone were distinguished 
from the background voxels within the volume of interest. This involved taking each 
image containing pixels along a grayscale continuum and declaring each as either black 
(background) or white (bone). A Gaussian filter with a sigma of 1.2 and support of 1.0 
was applied to reduce noise [62]. The threshold at which voxels were considered bone 
had to be chosen carefully to ensure that the 3D segment accurately represents the 
amount of bone and architecture of the bone. Following Scanco’s recommendations, a 
single global threshold value was applied to all samples in the study.  
 
This value for the appropriate global threshold was determined by the “gold 
standard” procedure of using an external method to verify the correct bone volume of the 
specimen [64]. In this case, analysis of histology slides served as the external method. 
Seven biopsies were found to have a µCT slice that matched one of the biopsy’s 
histology slides. The histological bone volume was found by defining the bone area under 
20x magnification (Axioplan 2 Imaging, Carl Zeiss, Thornwood, NY), and bone volume 
measurements were provided by the accompanying histomorphometry software 
(OsteoMeasureXP 3.0, OsteoMetrics, Inc., Decatur, GA). For each biopsy, µCT-based 
2D histomorphometry was completed multiple times using a different threshold value 
each time until the µCT-based bone volume matched the bone volume of the 
corresponding histology slice. The mean threshold value at which this occurred for the 
seven biopsies was 146 (units of 1/1000). This value was designated as the appropriate 
global threshold for the study. 
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Three biopsies in the study, however, were scanned with a density calibration 
applied. This is known to change the threshold value and therefore, required a different 
global threshold value. Using density-calibrated scans of the same seven biopsies as 
before, the same procedure of matching the bone volume to the corresponding histology 
slice was followed resulting in a threshold value of 214 for the density-calibrated 
biopsies. The resulting 3D segments were saved on the hard drive as a seg.aim files. 
 
Using the Scanco Image Processing Language (IPL) code, a surface tessellation 
language (STL) file was created from the seg.aim file for each biopsy. STL files are a 
commonly used format in CAD manufacturing and rapid prototyping to transfer 
geometry data. As part of this process, the surface of the 3D segment was smoothed as 
the bricklike voxels were triangulated into the surface mesh of the STL file. Upon 
creation, each STL file was transferred to the computer on which the FEA was run.  
 
Preprocessing of 3D Bone Models 
Once downloaded, the 3D model underwent a stage of preprocessing using 
Netfabb Basic (Netfabb GmbH, Lupburg, Germany). Netfabb provides a range of 
software products for use in 3D printing and additive manufacturing. Of their products, 
Netfabb Basic offers the lowest range of capabilities yet is freely distributed and met all 
study requirements. The program was used to reorient the cylindrical bone models so that 
the axis of loading was normal to the circular end face of the tested segment (Figure 8). 
Each virtual specimen was rotated along the x, y, and z axes until the alignment appeared 
correct from multiple points of view. For a more quantitative assessment, the correct 
alignment generally coincided with the minimum values for the x, y, and z dimensions. 
Angles of rotation were recorded. A 4 mm segment measured along the axis of loading 
was digitally cut from the middle of the straightest portion of trabecular bone. Aside from 
providing the desired segment length, cutting a portion from the middle of the virtual 
bone model ensured that both ends of the segment were flat in the plane normal to the 
axis of loading which was desired for both consistency and convenience in applying the 
boundary conditions of the FEA.  
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The preprocessing in Netfabb also served as a final check of the physical quality 
of the bone segment. The bone segment was aligned so that the shortest dimension of the 
segment corresponded to the biopsy depth estimated previously. The measure of the 
shortest dimension was recorded (minimum dimension). Fifty-five biopsies remained for 
FEA after samples were excluded for either insufficient trabecular bone, excessive 
processing, excessive influence of subcortical bone, or excessive bending or tapering.  
 
The last step within Netfabb involved an automatic repair of the STL geometry. 
Digitally cutting out the 4 mm segment often created holes in the surface mesh of the 
segment which was of primary concern as any holes would prevent the creation of a solid 
mesh. All biopsies underwent the automatic repair as a precaution. Nonmanifold edges, 
removal of double triangles and duplicate vertices were among the problems corrected as 
part of the automatic repair as well. A repair tolerance of 2 microns was acceptable as 
this fell well below the resolution of the microCT scan. The bone segments were now 
ready for mesh creation. 
 
Mesh Creation 
The STL mesh was just a shell defining the geometry; therefore, the creation of a 
volume mesh based on the STL was necessary to run a structural analysis. ANSYS ICEM 
CFD 14.5 (ANSYS® Academic Research, Release 14.5) was the program chosen to 
create the mesh. Mesh creation and refinement is an important step within the finite 
element method for determining how accurately the model will represent the response to 
the applied boundary conditions. After the STL file was imported into the program, 
ICEM was used to generate the mesh following user-defined settings. Although many 
bone FEA studies used hexahedral “brick” elements converted directly from the voxels, 
this study used tetrahedral elements. The reason for this difference was twofold: 1) 
preprocessing required the transition to an STL which smoothed the voxels into a 
triangulated shell making a direct conversion to brick elements impossible, and 2) while 
tending to be artificially stiffer compared to hexagonal elements, the tetrahedral elements 
could more accurately represent the complexity of the geometry. 
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The Octree Method was the algorithm chosen for automatic creation of the 
tetrahedral mesh. This method was first developed in the 1980’s and worked by enclosing 
the entire geometry in a uniform tetrahedral mesh. The large elements were then 
subdivided into smaller elements until the desired resolution and constraints were 
achieved. Following conformation of the elements to the geometry surfaces, elements 
outside of the geometry were removed. Mesh smoothing by moving and merging nodes 
and deletion of poor elements finished the method. 
 
Automatic Mesh Creation Settings 
Previously, a convergence study was conducted to determine the appropriate 
settings for the automatic mesh creation [58]. In general, a smaller and thus, a greater 
number of elements would result in more accurate results. However, more elements also 
would require more equations that must be solved which could progress to a computation 
requirement beyond the available software and hardware capabilities. The goal of the 
convergence study was to find the parameter values that would provide reasonably 
accurate results with the least computational cost. The focus was chiefly on adjusting the 
global maximum element size, the minimum element size, the edge criterion, and mesh 
coarsening.  
 
The global maximum element size defines the seed element size that produces a 
uniform mesh. To satisfy the computation requirements of the Octree method, the defined 
value should be a factor of 2. The rest of the parameters under scrutiny fall under the 
process of mesh refinement. Mesh refinement acknowledges that especially in a complex 
geometry, certain locations will experience greater variations in stress over others and 
will, therefore, require a finer mesh to accurately describe these variations. For example, 
a sharp corner will experience an abrupt rise in stress requiring a much finer mesh in 
comparison to a uniform flat surface. The minimum element size defines the limit for 
how small an element can be as the mesh refinement attempts to capture curvatures in the 
geometry. The edge criterion is a value from 0 to 1 that defines how exact sharp edges of 
the geometry will be represented with values approaching 0 being the most exact. 
Reducing this value increases mesh refinement but may also lead to the creation of 
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elements of poor quality (i.e., extremely acute angles). Coarsening the mesh is a final step 
of enlarging unnecessarily small elements where possible in the interior of the model to 
reduce the number of elements without affecting the mesh’s ability to capture features. A 
limit on the allowable aspect ratio restrains how much coarsening occurs. 
 
As a result of the convergence study, the global maximum element size was set at 
0.250 mm. Also included in the global mesh parameters, the scale factor was set at 1 
since the geometry from the imported STL file was automatically in the actual 
dimensions of the bone segment. Curvature/proximity based refinement was enabled to 
optimize computational cost. This parameter allows for the use of smaller elements to 
more accurately capture local curvatures but also limits the cost by defining a minimum 
element size. The minimum size limit of 0.050 mm resulted from the convergence study. 
As previously stated, a mesh type of tetrahedral elements created using the Octree 
Method was set within the volume meshing parameters. Also within the volume 
parameters, the optimal edge criterion was determined to be 0.050 by the convergence 
study. Preserving the default settings, the smooth mesh option was enabled and set to run 
five iterations with a minimum quality of 0.4 as a constraint. Per the convergence study, 
the coarsen mesh option was enabled to reduce element number over two iterations with a 
worst aspect ratio of 0.2 as a limit. All parameters were automatically fixed to their 
settings using a script file. 
 
Mesh Quality Inspection 
Once the settings were finalized, the creation and refinement of the mesh 
commenced. The process took approximately 5 minutes per biopsy to complete. A quality 
check was then necessary before proceeding. Upon creation of the mesh, all connected 
elements were considered to be a single material. Free-floating elements had to be deleted 
for all elements in the analysis to be properly constrained. These elements arose from 
various stages of the process including inability of the mesh to capture extremely small 
connections, connections lost as the segment was cut in Netfabb, and free-floating pieces 
of bone embedded in the PMMA block. Fortunately, they were easily removed once the 
primary material was identified; all other mesh materials were selected and deleted.  
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A further visual inspection as well as a quantitative assessment of the mesh 
quality was conducted on the remaining volume mesh (Figure 9). Mesh quality was 
assessed numerically based on element aspect ratios and angle idealization [50]. The 
aspect ratio quantifies how close the shape of the element is to the ideal. The values range 
from 0 to 1 with 1 representing the ideal tetrahedral element with equilateral sides. Poor 
quality was defined as an element with an aspect ratio less than 0.33. Only one biopsy 
had a mesh containing greater than the recommended 5% of elements considered poor at 
5.61%. The mean percentage of poor elements by aspect ratio was 2.58%. Quality was 
also assessed with the criterion of maximum dihedral angle. The acceptable range for 
dihedral angles was between 30° and 150° [65]. The mean percentage of poor quality 
elements by maximum dihedral angle was 0.01% with all meshes falling well below the 
recommended 5% threshold. Once the mesh was verified, an ANSYS .in file was created 
to import the mesh into ANSYS Mechanical APDL. Of particular note in running this 
command, the mesh for analysis included only the volume elements and no bar or shell 
elements. 
 
Finite Element Analysis 
Finite element analysis of the models was conducted using APDL code for a 
batch analysis in ANSYS Mechanical (ANSYS® Academic Research, Release 14.5). 
This commonly used software was chosen for its availability within the laboratory, ease 
of use, and vast range of capabilities including nonlinear analyses, optimization studies, 
buckling, and drop-out of failed elements. The code for an automated batch analysis was 
previously developed [58]. A simulated 1% strain compression test was chosen as the 
mode of analysis. Numerous studies have verified that compression simulations using 
FEA accurately reproduce the results of mechanical compression tests where a bone 
segment is physically crushed [48, 53, 54, 56]. For all the models, solid 4 node brick 
(solid185) elements were used and were defined by the imported mesh .in file.  
 
Assignment of Material Properties 
Once the elements were defined, material properties were assigned. Each finite 
element model consisted of a single material whose properties were considered to be 
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isotropic, linear elastic, and uniform with a Poisson ratio of 0.3 and a Young’s modulus 
of 16.0 GPa. Although bone is an anisotropic material, the assumption of isotropic 
material properties was shown to be reasonable and significantly simplifies the analysis 
because of the complexity of the trabecular geometry. The value for Young’s modulus for 
the tissue fell within the range of reported values for trabecular bone [66]. 
 
Application of Boundary Conditions 
Defining the test conditions was the next step after the model properties were set. 
Boundary conditions were applied fixing the displacement and rotation to zero for the 
nodes at the bottom 5% of the model to prevent rigid body motion. Nodes in the top 5% 
were subjected to a displacement of 1% compressive strain in the y-direction while the 
remaining displacements and rotations were fixed at zero (Figure 10). The constraints 
were similar to a mechanical compression test using end caps. Because of the boundary 
conditions, only the middle 90% of each bone segment contained useful information 
regarding the reaction stresses.  
 
FEA Output 
Output of the FEA included the volume of the elements in the model (Bone 
Volume), the bone segment length (Length) and the total reaction force along the axis of 
loading. Additionally, an estimate of the force required to induce failure was calculated 
during the post-processing within ANSYS. Overall segment failure could be assumed 
when 2% of the stressed bone volume reached an equivalent strain of 0.7% [54]. The 
force required to meet this criteria was recorded in the output as the ultimate force. 
Further visual assessment of the response of the bone segment to the loading conditions 
was conducted through the creation of contour plots (Figure 11). These plots revealed 
where the bone segment was weakest. 
 
CT-based Histomorphometry 
Gathering 3D histomorphometry data was required before all calculations could 
be completed. Using the previously recorded angles from the realignment in Netfabb, the 
microCT images were realigned and reconstructed to simplify defining the volume of 
interest specific to the 4mm section. The approximate location of the 4mm segment was 
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based on the distance between the topmost point of the entire biopsy volume and the top 
of the 4mm segment as well as the angle of the rotation into the slices of the scan (offset 
angle). To save time, refinement of the contouring which defined the area of interest was 
limited to the approximate location of the 4mm segment along with an extra 2mm at each 
end (Figure 7). Because the offset angle could not be corrected, the region of interest for 
3D evaluation had an oversized length of 136 voxels (4.08mm) and was centered on the 
4mm segment used for FEA. The same values previously applied to the 3D segmentation 
parameters (i.e., global threshold, Gaussian sigma and support) were used again. A 3D 
visualization of the region of interest in Scanco’s 3D evaluation window was compared 
to the segment in Netfabb in order to ensure that the same location was analyzed. 
Relevant results included the total volume (µCT TV), connectivity density (CD), 
structure model index (SMI), trabecular thickness (Tb.Th.), and trabecular separation 
(Tb.Sp.). SMI is a quantification of the trabecular structure with zero representing a more 
plate-like structure and three representing a more rod-like structure. All reported values 
were calculated without the assumption of a plate model. 
 
Post-Processing 
The cross-sectional area used to determine stress and modulus values was 
calculated by dividing the microCT-based total volume of interest by the length of the 
volume of interest while taking into account the offset angle. 
  
𝐴𝑟𝑒𝑎 =  
µ𝐶𝑇 𝑇𝑉
µ𝐶𝑇 𝐿𝑒𝑛𝑔𝑡ℎ ∗ 0.030 cos(𝑜𝑓𝑓𝑠𝑒𝑡)⁄
 
 
The ratio of bone volume to total volume (BV/TV) of each 4mm segment was 
calculated using the volume of the mesh elements and the product of the cross-sectional 
area and segment length.  
 
𝐵𝑉 𝑇𝑉⁄ =  
𝐵𝑉
𝐴𝑟𝑒𝑎 ∗ 𝐿𝑒𝑛𝑔𝑡ℎ
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Apparent Young’s modulus was defined as the reaction stress divided by the 
strain boundary condition and is a measure of the rigidity of the entire tissue volume. 
Another modulus value, the effective Young’s modulus, normalized the apparent 
Young’s modulus to the BV/TV thus providing insight into how efficiently the structure 
made use of available material. Finally, the estimated failure stress was determined by 
dividing the ultimate force by the cross-sectional area and provided an estimation of the 
stress at which failure of the segment would occur.  
 
The apparent modulus, effective modulus, and failure stress were multiplied by a 
correction factor to account for the effect of lost connections in the trabecular network 
around the periphery of the segment [67]. These sources of error are known as side 
artifacts. The outer perimeter with a thickness of approximately half the trabecular 
separation is a region where load-bearing capacity is likely compromised due to side 
artifacts. The correction factor was calculated as a ratio of the measured cross-sectional 
area to the true cross-sectional area defined as just the inner core where the load-bearing 
capacity was not compromised.  
 
Statistical Analyses 
All resulting data was subjected to statistical analyses using SAS 9.3 (SAS 
Institute Inc., Cary, North Carolina).  General linear regression models (PROC GLM in 
SAS) were used to first relate the biomechanical response variables (e.g. apparent 
modulus, effective modulus, and predicted failure stress) to duration of bisphosphonate 
treatment, specimen cross-sectional area, and subject characteristics such as age. Effect of 
treatment duration was modeled using polynomial regression. Fit of the models were 
tested using residual variability among subjects with the same treatment duration and 
adjusted for covariates. The microCT-derived structural response variables (e.g. BV/TV, 
SMI, CD, Tb.Th., and Tb.Sp.) were also related to these independent variables. Finally, 
polynomial regression models were used to relate the biomechanical response variables 
to the microCT-derived structural indices to determine which indices were the most 
significant predictors of the biomechanical properties. A p<0.05 was considered 
statistically significant. 
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Three assumptions are made in linear regression models: 1) the response variables 
are best described as a linear function of the independent variables, 2) the error terms are 
independent of each other, and 3) for any value of the independent variables, the 
corresponding value of the response variable is normally distributed with equal variance 
about the mean response for all values of the independent variables [68]. Plots of the 
response variables vs. the independent variables with the prediction equations 
superimposed were generated to examine the fit of the models. The Kolmogorov-
Smirnov test was conducted to check the assumption of normality and homogeneity of 
errors. In case of failure to meet this assumption, an appropriate transformation was 
applied.  
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Figure 4. Biopsy embedded in PMMA. 
Figure 5. Progression of sample eligibility. 
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Figure 7. MicroCT slice with contour 
lines (green) indicating the volume of 
interest. 
Figure 6. Initial check of biopsy depth. 
25 
 
 
Figure 9. Tetrahedral mesh of a 3D bone model generated in ANSYS ICEM CFD. 
Figure 8. 3D bone model rotated, cut to a 4mm length, and repaired in 
Netfabb Basic. 
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Figure 11. Visual assessment of the load distribution throughout the bone 
segment from FEA with red indicating the weakest locations. 
Figure 10. Boundary conditions applied to the ends of the specimen. 
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Results 
Fifty-three subjects were included in the analysis after two were excluded. One 
subject was excluded due to abnormal loading conditions caused by large voids at the 
constrained ends of the bone segment. Another was excluded after investigation of the 
subject’s medical history revealed bisphosphonate treatment began at age 32. 
 
Average cross-sectional area was not found to have a significant contribution to 
the prediction of any of the response variables when adjusted for age and treatment 
duration. These variables included apparent modulus, effective modulus, failure stress, 
bone volume fraction (BV/TV), structure model index (SMI), connectivity density (CD), 
trabecular thickness (Tb.Th.), and trabecular separation (Tb.Sp.). Therefore, cross-
sectional area was removed from the regression models. Heterogeneity in the response 
variables at different treatment durations was revealed by the Kolmogorov-Smirnov tests. 
Square root transformations were applied to all of the response variables to resolve the 
heterogeneity. 
 
Apparent modulus was significantly predicted by age and a linear and quadratic 
term for duration of treatment (Table 1). The prediction equation for apparent modulus 
increased, reached a maximum at a treatment duration of 7.16 ± 0.67 years (Constance 
Wood, personal communication, July 21, 2014), and then decreased (Figure 12a). 
 
Similar results were obtained with the effective modulus and estimated failure 
stress as functions of age and duration of treatment (Table 1). The prediction equation for 
effective modulus increased, reached a maximum at a treatment duration of 7.07 ± 0.65 
years (Constance Wood, personal communication, July 21, 2014), and then decreased 
(Figure 12b). The prediction equation for failure stress increased, reached a maximum at 
a treatment duration of 7.06 ± 0.64 years (Constance Wood, personal communication, 
July 21, 2014), and then decreased (Figure 12c). 
 
All of the reported structural indices except for trabecular thickness were 
significantly predicted by age and a linear and quadratic term for treatment duration 
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(Table 1). The prediction equations for BV/TV (Figure 12d) and connectivity density 
(CD, Figure 13a) increased, reached a maximum, and then decreased. The maximum 
occurred at 6.88 ± 0.69 years for BV/TV and at 6.84 ± 0.98 years for CD (Constance 
Wood, personal communication, July 21, 2014). The prediction equations for SMI 
(Figure 13b) and Tb.Sp. (Figure 13c) decreased, reached a minimum, and then increased. 
The minimum occurred at 6.58 ± 0.87 years for SMI and at 6.83 ± 0.96 years for Tb.Sp 
(Constance Wood, personal communication, July 21, 2014). 
 
Individually, all the microCT-derived structural indices were significant 
predictors of the FEA-derived biomechanical properties (Table 2). BV/TV (Figure 14a) 
and SMI (Figure 14b) were the strongest predictors of apparent modulus, effective 
modulus, and failure stress. In addition, the analysis was completed with all the structural 
indices included as independent variables in the regression model. In this case, only 
BV/TV and SMI significantly contributed to the prediction of the biomechanical 
variables. Together, microCT-derived BV/TV and SMI were able to explain 81.5% of 
apparent modulus, 60.4% of the effective modulus, and 86.1% of the failure stress (Table 
2). 
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Table 1. Linear Regression Correlation Coefficients of FEA and MicroCT Measurements 
Regressed on Age and Duration of Bisphosphonate Treatment 
 
  
Response 
Variable Intercept Age Duration Duration2 Vertex R2 
Eapp 1.326 -0.015 0.117 -0.008 7.16 0.325 
Eeff 2.832 -0.027* 0.241 -0.017 7.07 0.311 
Pfail 3.265 -0.032 0.239 -0.017 7.06 0.347 
BV/TV 0.579 -0.004 0.023 -0.002 6.88 0.382 
SMI 1.061 0.007* -0.050 0.004 6.58 0.230 
Tb.Sp. 19.753 0.111 -0.474* 0.035 6.83 0.299 
CD 3.099 -0.021* 0.121* -0.009* 6.84 0.218 
Note:*p<0.05. p<0.01 for all unmarked coefficients.  
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A B 
C D 
Figure 12. Relationships between bisphosphonate treatment duration and (a) apparent 
modulus, (b) effective modulus, (c) failure stress, and (d) bone volume fraction. The solid 
trendlines are fitted to the raw data; the dotted trendlines are fitted to subject age(63 
years)-adjusted data. 
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A 
B 
C 
Figure 13. Relationships between 
bisphosphonate treatment duration and (a) 
connectivity density, (b) structure model index, 
and (c) trabecular separation. The solid 
trendlines are fitted to the raw data; the dotted 
trendlines are fitted to subject age(63 years)-
adjusted data. 
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 Table 2. Linear Regression R2 Values of FEA Measurements Regressed on MicroCT 
Measurements 
 
   
Independent 
Variable(s) 
  
Eapp Eeff Pfail 
BV/TV 0.782 0.542 0.831 
SMI 0.606 0.507 0.626 
Tb.Sp. 0.259 0.195 0.263 
CD 0.163 0.150 0.156 
Tb.Th 0.230 0.134 0.266 
BV/TV and SMI 0.816 0.604 0.861 
Note: p<0.01 for all models.   
A B 
Figure 14. Linear correlations of (a) Bone volume fraction and (b) SMI with apparent 
modulus. 
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Discussion 
The key findings of this study were the following:  
1.  The duration of bisphosphonate treatment was significantly related to 
trabecular bone microarchitecture and the calculated mechanical properties of 
trabecular bone. 
2. The initial positive associations of bisphosphonate treatment with bone 
microarchitecture and with the calculated mechanical properties of trabecular 
bone were observed through approximately 6-7 years of continuous treatment. 
3. Beyond approximately 6-7 years, the relationships between bisphosphonate 
treatment and bone microarchitecture and mechanical properties were no 
longer positive. 
4. Moreover, the average values per year of treatment for bone microarchitecture 
and mechanical properties began to decline. At extremely long durations, 
these properties were potentially worse than the values of these parameters for 
untreated bone. 
5. BV/TV and SMI were significant predictors of the calculated mechanical 
properties of trabecular bone and contributed significant information 
independent of each other. 
 
This study provides novel insight into the effects of long-term bisphosphonate 
treatment on trabecular microarchitecture. Previous studies have examined the 
relationships between treatment duration and the structural indices. In studies of up to 3 
years of treatment, bisphosphonates have been shown to at least preserve 
microarchitecture with trends toward an increase in BV/TV and a decrease in trabecular 
separation [33-35]. Furthermore, a previous study incorporating FEA has reported an 
increase in trabecular strength after a year of ibandronate [36]. Another study noted an 
increase in stiffness and failure load in the tibia after 2 years of bisphosphonates, 
although the change from baseline was not significant [37]. These studies support the 
initial positive outcomes linked to bisphosphonates. However, the treatment durations of 
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these studies were too short to comment on the negative trends associated with longer 
durations of treatment.  
 
Little was previously known about the effects of long-term bisphosphonate 
treatment on bone quality other than its relationships with BMD and turnover [38]. While 
studies of BMD have supported the assumption of continued efficacy [29, 38], concerns 
have arisen over reports of atypical femoral fractures occurring during bisphosphonate 
treatment with a greater prevalence linked to long-term duration of treatment [40, 42, 69, 
70]. This study provided valuable information regarding the correlations between long-
term bisphosphonate treatment and measures of bone quantity and bone 
microarchitecture, a key component of bone quality.  
 
The prediction equations of this study noted a parabolic relationship between the 
structural state of trabecular bone and long durations of bisphosphonate treatment. The 
duration of treatment range at which the average mechanical competency decreased, 
above approximately 7 years, was similar to the duration of treatment ranges where 
incidence rates of atypical fractures have been reported to be highest [69, 70]. In the 
present study, the calculated biomechanical properties based on the structure and volume 
fraction alone were no worse for subjects at 11 years of treatment than for those at 3 
years. Studies reported an increase in atypical fracture rates with duration of treatment 
[69, 70]. The largest increase in the age-adjusted atypical fracture rate occurred going 
from the 6.0-7.9 years of treatment grouping to the 8.0-9.9 years of treatment grouping 
[69]. This suggests that while a decline in bone quantity and microarchitecture likely 
contributed to the prevalence of atypical fractures, aspects of bone quality not analyzed in 
the present study may be effected by longer treatment durations in a way that 
compromises bone strength.  
 
It is important to stress that the correlations reported between bisphosphonate 
treatment and the calculated biomechanical properties and microCT-derived structural 
indices were independent of the previously reported influence of specimen size and age 
on bone specimen mechanical properties [71]. The size of the bone specimens used were 
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smaller in comparison to many other FEA studies of trabecular bone. However, no 
significant independent effects of bone cross-sectional area on the any of the response 
variables were reported. Age was significantly correlated to a decline in bone 
microarchitecture and mechanical properties, but the correlations found with age and the 
correlations found with treatment were independent of each other. Therefore, the declines 
in bone quantity, microarchitecture, and mechanical properties observed with long-term 
treatment cannot be attributed to the effects of aging. 
 
Increase in subject age corresponded to poor bone quality based on all of the 
structural indices examined including BV/TV, SMI, CD, Tb.Th., and Tb.Sp. This agrees 
with numerous reports of declines in bone structure with age as demonstrated by a 
negative correlation with BV/TV, Tb.Th., and CD and a positive correlation with Tb.Sp. 
and SMI [72-77]. Of the mechanical measurements, apparent modulus and ultimate stress 
have been shown to decrease with age in the elderly using tibial bone in a mechanical 
compression test [78]. Although these studies do not address bisphosphonate treatment, 
they indirectly support the credibility of the methods used in this study to find significant 
correlations between treatment duration and bone microarchitecture and mechanical 
properties. 
  
The apparent modulus can be described as a measure of the rigidity of the entire 
bone segment prior to the onset of plastic, or permanent, deformation. The apparent 
modulus as well as the effective modulus and estimated failure stress were isolated to the 
mechanical contributions of bone quantity and microarchitecture. This was because a 
constant tissue modulus was used throughout and other bone quality factors, such as 
microdamage and variations in mineralization, were not captured by the model used.  
Hence, bisphosphonate treatment initially was associated with an increase in the average 
rigidity due to the trabecular microarchitecture and volume, a maximum at approximately 
7 years, and then a decline in the average rigidity. 
 
Although the apparent modulus is limited to describing mechanical behavior prior 
to the yield point, it has been shown to be a predictor of bone strength [52]. This was 
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confirmed in the present study by the strong correlation between apparent modulus and 
failure stress (R2 = 0.98). With this in mind, the apparent modulus and failure stress 
results provided insight into the trabecular bone’s propensity to fracture. The 
contributions of bone quantity and microarchitecture to overall bone strength were 
greatest when apparent modulus and failure stress reached their maximum, approximately 
7 years of bisphosphonate treatment. Beyond this duration of treatment, the load required 
to induce fracture decreased. 
 
As a ratio of rigidity to percent bone volume, the effective modulus described 
how efficient the trabecular structure was in contributing to bone strength. While the 
measurement wasn’t free from the influence of BV/TV, the influence of BV/TV was 
reduced, and the influence of trabecular structure was emphasized in the process. 
Trabecular bone was most efficient, or most rigid per bone fraction, at approximately 7 
years of bisphosphonate treatment and then declined. 
 
The trend of an initial positive association with bisphosphonate treatment 
followed by a negative association was evident in the relationship between treatment 
duration and BV/TV, SMI, CD, Tb.Th., and Tb.Sp. as well. The correlations taken 
together may provide insight into the mechanisms by which bone microarchitecture 
changes with duration of treatment. The response curve predicting the density of 
trabecular connections and the response curve relating trabecular separation to duration 
of treatment were similar in shape but the inverse of each other. Bisphosphonates may 
initially increase connectivity while concurrently reducing the space between trabeculae. 
Both improvements were reversed after extrema were reached at approximately 7 years 
of treatment. Trabecular thickness remained unchanged by bisphosphonate treatment, 
further suggesting that the variation in bone volume was driven by changes in trabecular 
connectivity. 
 
Of the structural indices measured, SMI was the most unique being more deeply 
rooted in structure and less descriptive of bone quantity compared to the other indices. 
Analysis of SMI revealed that bisphosphonate treatment was initially associated with a 
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trend toward more plate-like bone followed by a reversal toward more rod-like bone. 
Previous studies have linked rod-like trabecular structures to osteoporosis and a 
decreased resistance to fracture [74, 79]. 
 
The uniqueness of the SMI measurement likely reduced the potential for 
collinearity with BV/TV that Tb.Sp. and CD appeared to show when modeled as 
predictors of the apparent modulus, effective modulus, and failure stress. BV/TV was the 
strongest single predictor of the biomechanical properties. This supported the attention 
placed on bone loss in diagnosing and monitoring osteoporosis. SMI, however, provided 
significant structural information independent of BV/TV in predicting the biomechanical 
properties. BV/TV and SMI together were significantly better at predicting the 
biomechanical properties than when considered separately. This further emphasizes the 
importance of piecing together multiple aspects of bone quantity and quality to provide a 
more complete picture of the bone’s mechanical competency. Previous studies have 
shown that BV/TV, SMI, and even Tb.Sp. are each capable individual predictors of 
biomechanical properties [75, 80-82]. The best model to predict apparent modulus, 
effective modulus, and failure stress from microCT-derived structural indices included 
both BV/TV and SMI.  
 
The initial positive effects on bone microarchitecture are in accord with the 
known mechanism of action of bisphosphonates. Bisphosphonates target osteoclasts to 
inhibit resorption and have been reported to promote bone formation as well [83]. This 
leads to a net gain in bone which can be observed by the increased BV/TV associated 
with initial treatment. Bone quality is improved along with bone quantity as the 
additional bone material is arranged to improve microarchitecture. This is evident in the 
increase in the averages for CD and SMI while Tb.Sp. decreased. The increase in 
effective modulus also indicates that the additional bone led to greater structural 
efficiency for subjects in the initial years of treatment. 
 
Eventually, the balance in favor of formation is lost and beneficial effects of 
bisphosphonate treatment on quantity and microarchitecture plateau. Decreased 
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resorption likely leads to a decrease in formation based on the relationship between 
osteoblast and osteoclast activity. Another possibility is that continuous bisphosphonate 
uptake increases the drug concentration that reaches the osteoblasts. At a higher 
concentration, bisphosphonates shift from promoting osteoblastogenesis to causing 
apoptosis of both osteoclasts and osteoblasts [84]. Either scenario could explain why 
bisphosphonate treatment decreases bone turnover and does not continue to increase 
quantity and improve microarchitecture indefinitely.  
 
Rather than a steady plateau, the results of this study showed eventual declines in 
bone quantity and microarchitecture with treatment duration. Without the ability to repair 
itself through remodeling, bone becomes susceptible to failure at reduced stresses from 
wear and fatigue. By inhibiting both bone resorption and formation, long-term 
bisphosphonate use may increase the potential for microdamage to go unrepaired. While 
microdamage was not considered in the present study, the consequences of accumulated 
microdamage may have been observed. The decline in BV/TV and CD accompanied by 
an increase in Tb.Sp. may reflect the loss of trabecular struts that have broken away due 
to the microdamage.  Microcracks are known to grow and coalesce with continued 
repetitive loading [85]. Thus, bone mass isn’t just lost; it is lost at key load-bearing 
structural junctions. The decreasing bone quantity and microarchitecture quality together 
lower the stress that the bone can withstand before fracturing. 
 
Limitations 
One of the limitations of this study was its cross-sectional nature. As such, each 
datum offered insight limited to the date that the biopsy was performed. Although some 
inferences could be assumed, the state of bone in each subject prior to or after the biopsy 
remained uncertain. It is not possible to definitively state that any or all of the subjects 
would have experienced the same initial positive outcomes followed by a decline after 7 
years of treatment. To execute a longitudinal study of bisphosphonate treatment to the 
length captured in the present study does not appear feasible as it would require a biopsy 
from all subjects at each year of treatment. The design of this study best suited the 
resources available and still succeeded in meeting the study aims. 
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The biopsies collected and used for this study were from cores of either 3 or 4 mm 
diameter. According to the most widely accepted recommendations [60], the size of many 
of the biopsies used in this study were near the lower limit of the recommended five 
intratrabecular lengths. This standard for representation of the true in situ behavior has 
since been reexamined [71]. Their findings indicated that the apparent modulus 
calculated by FEA continued to increase as the diameter of the trabecular bone segment 
increased rather than converging on a constant modulus. Therefore, the apparent modulus 
values reported in this study cannot be assumed to be the accurate in situ value; rather, all 
presently reported values were undervalued according to the results of this prior study 
[71]. Going from independent cores to in situ, the apparent moduli of 2.81 mm and 3.96 
mm vertebral cores increased 19.73% and 17.59%, respectively [71]. By limiting the 
range of specimen sizes, the relative differences between samples remained valid. Any 
error associated with the effect of specimen size in the form of side artifacts was 
corrected as recommended [86]. This was supported by the lack of significance of cross-
sectional area as a predictor of any of the response variables. The values reported, 
therefore, are suitable as a comparative dataset; however, a larger specimen size would be 
desired to obtain a more accurate individual assessment of fracture risk. 
 
Another potential limitation to this study was the use of a linear FEA rather than a 
nonlinear FEA. Although apparent modulus has been shown to correlate to bone strength 
and subsequently fracture resistance [53, 54], to definitively say that an increase or 
decrease in apparent modulus with bisphosphonate treatment is equivalent to an increase 
or decrease in fracture resistance with treatment assumes that the relationship between 
apparent modulus and fracture stress remains constant throughout the treatment duration. 
Until this assumption is validated, inferences about fracture with use of bisphosphonates 
must be interpreted with caution. Further mechanical testing examining the post-yield 
behavior of trabecular bone in response to bisphosphonate treatment is required. Such a 
study would also provide validation for a nonlinear analysis. Until this task is achieved, a 
nonlinear FEA would be no more reliable than this linear FEA study. 
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 Finally, a greater sample size would increase the credibility of the study. Despite 
the large number of biopsies collected by the Kentucky Bone Registry, only 53 subjects 
met the established medical and biopsy quality criteria in order to be included in this 
study. This was less than the goal of 70 subjects set in the study design. It was especially 
hard to find subjects who had maintained continuous oral bisphosphonate treatment or 
greater than 12 years without having another medical reason for exclusion. The addition 
of samples in this range of treatment duration would instill greater confidence in the 
observation of the negative trends associated with these higher treatment durations. Given 
that the p-values for many of the significant relationships were less than 0.01, however, 
there is good reason to believe that the significant relationships would hold true with an 
increase in sample size.  
 
Future Studies 
To further assess the effects of long-term treatment, other aspects of bone quality 
must be accounted for in the model as well. A logical next step would be to add in 
aspects of trabecular bone tissue properties beginning with the tissue modulus specific to 
each bone segment. Nanoindentation is an established tool for determining the material 
properties of biological tissue [87]. Young’s modulus of trabecular bone from 
nanoindentation of each biopsy could easily be coded into the FEA, and the combination 
of nanoindentation and FEA has been shown to be a robust method for predicting linear 
elastic mechanical properties [48]. 
 
Another option is the assignment of material properties based on microCT density 
measurements. An equation relating density to the tissue modulus could be used to assign 
the appropriate tissue modulus to each element of the mesh. With the material properties 
of each element as a product of the degree of mineralization, variations and defects in 
mineralization of the bone segment can be included in the FEA. 
 
Microdamage is another aspect of bone quality that would benefit from inclusion 
in a study of long-term bisphosphonate treatment. Although the results weren’t quite 
significant, an increase in markers of microdamage in subjects treated with alendronate 
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for a mean of 63.6 months compared to placebo has been observed [88]. Ideally, the finite 
element model would account for microdamage as well. Greater image resolution would 
be required for the presence of subject specific microcracks in the model.  
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Conclusion 
 The present results show that beneficial contributions to trabecular failure 
strength, apparent modulus, and effective modulus peak at approximately 7 years of 
continuous bisphosphonate treatment then decline. Similar correlations were noted 
between duration of treatment and BV/TV, SMI, CD, and Tb.Sp. The relationships noted 
between bisphosphonate treatment duration and failure strength, apparent modulus, 
effective modulus, BV/TV, SMI, CD, and Tb.Sp. were independent of age and bone 
turnover. These findings confirmed that bisphosphonates provide short term benefits and 
contribute new information showing these benefits decline after reaching a maximum at 
approximately 7 years of treatment. These results suggest that bisphosphonates should 
not be prescribed without a defined endpoint, that other aspects of bone quality not in the 
present study may be declining with long-term treatment, and that the microCT derived 
measures of BV/TV, representing bone quantity, and SMI, representing bone 
microarchitecture, together adequately predict bone mechanical properties if FEA is 
unavailable. 
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APPENDIX: EXPLANATION OF VARIABLES 
NOTE: Related variables are in red 
 
 Age: Age of the patient on the date the biopsy was taken 
 Duration of Treatment in Years (Duration): Total time that the patient had 
been continuously treated with bisphosphonates prior to date of biopsy 
 Threshold: The lower grayscale threshold value used to dictate what is bone 
when creating a 3D segment from microCT images. Voxels with a grayscale 
intensity above the threshold are considered bone. 
 
Input for FEA 
 Young's Modulus Trabecular Bone (Emat): This is the stress per unit strain of 
the trabecular bone measured on the nanoscale and is in units of GigaPascals 
(GPa). An arbitrary value of 16 GPa was assigned to all the samples. 
Direct Output of FEA 
 Reaction Force (Fy): This the total reaction force along the axis of loading (y-
axis) measured in Newtons (N). 
 Bone Volume (BV): The total volume of the elements in the mesh which is the 
volume of bone material in the segment being analyzed. Measured in millimeters 
cubed (mm^3) 
 Segment Length (Length): The length of the bone segment along the axis of 
loading (y-axis). Each biopsy was cut so that this value is a constant 4.00 mm. 
 Ultimate Force (Fult): An estimate of the force along the y-axis required to 
cause overall failure of the biopsy segment. This is a calculation of the force at 
which 2% of the stressed bone volume reaches an equivalent strain of 0.007. 
Value reported in Newtons. 
 
Direct Output of MicroCT 3D Evaluation 
 MicroCT Total Volume (µCT TV): Total volume of the region of interest which 
is defined by contour lines drawn on each 2D slice. This includes both the bone 
and the porosity (bone marrow). Value reported in units of millimeters cubed. 
 MicroCT Length (µCT Length): length along the y-axis of the biopsy segment 
analyzed in the 3D evaluation. Value reported in units of voxels where each voxel 
is 0.030 mm in length. 
 Connectivity Density (CD): Estimate of the trabecular connectivity per unit 
volume. It is a measure of bone architecture and is reported in units of millimeters 
cubed. 
 Structure Model Index (SMI): This is a gauge of whether the bone segment is 
more platelike or more rodlike in structure. Values range from 0 (parallel plates) 
to 3 (cylindrical rods). SMI is based on the curvature of the structure, so a value 
of 4 would correspond to a sphere, and a negative SMI value means that the 
surface is concave. Negative values are typically encountered when the BV/TV is 
high and cortical or subcortical bone is being measured. 
 Trabecular Thickness (Tb.Th.): Average thickness of the trabeculae. Value 
reported in units of microns. 
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 Trabecular Separation (Tb.Sp.): Average thickness of the bone marrow. Value 
reported in units of microns. 
 
 
 
Values Measured in Netfabb 
 Minimum Dimension (MinDim): Measure of the shortest dimension of the bone 
biopsy segment. For whole biopsies, this would be the diameter of the bone 
cylinder. For cut biopsies, this value is the remaining portion of the diameter and 
is important in deciding whether or not the biopsy is useable. Value reported in 
millimeters. 
 Offset Angle (Offset): The angle at which the bone segment for FEA differs from 
the segment analyzed in the microCT 3D evaluation. This is the angle of the 
biopsy going into the microCT slices and cannot be corrected for the 3D 
evaluation. Value reported in degrees. 
 
Calculated Values 
 Cross-Sectional Area (Area): The average area of the biopsy segment 
perpendicular to the axis of loading (y-axis). The following equation is used in the 
calculation: 
𝐴𝑟𝑒𝑎 =  
𝑢𝐶𝑇 𝑇𝑉
𝑢𝐶𝑇 𝐿𝑒𝑛𝑔𝑡ℎ ∗ 0.030 cos(𝑜𝑓𝑓𝑠𝑒𝑡)⁄
 
 
 BV/TV: The ratio of the Bone Volume to the total volume of the biopsy segment. 
Since the microCT Total Volume is not of the exact same bone segment used in 
the FEA, the total volume is calculated as a product of the Length and the Cross-
Sectional Area. The following equation is used in the calculation: 
 
𝐵𝑉 𝑇𝑉⁄ =  
𝐵𝑉
𝐴𝑟𝑒𝑎 ∗ 𝐿𝑒𝑛𝑔𝑡ℎ
  
 
 Reaction Stress (Py): This the total reaction stress along the axis of loading (y-
axis) calculated by dividing the Reaction Force by the Cross-Sectional Area. 
Value is reported in units of MegaPascals (MPa). 
 Side Artifact Correction Factor: This is a correction factor applied to the 
biomechanical variables because of connections lost around the perimeter of the 
bone segment. It is the ratio of the measured cross-sectional area to the true cross-
sectional area. The true cross-sectional area is the measured cross-sectional area 
excluding the region of lost connections which has a thickness equal to half the 
trabecular separation. 
 Apparent Young’s Modulus (Eapp): This is a commonly reported measure of 
strength of the biopsy segment and is calculated by dividing the Reaction Stress 
by the strain applied to the biopsy segment and multiplying by the Side Artifact 
Correction Factor. The strain is a boundary condition of the FEA and is a constant 
arbitrary value of 0.01. Value is reported in units of GigaPascals (GPa). 
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 Effective Young’s Modulus (Eeff): This value is an attempt to normalize the 
Apparent Young’s Modulus values to the same BV/TV. Thus, it is a measurement 
of how efficiently the bone material is structured to contribute to the segment’s 
rigidity. It is calculated by dividing the Apparent Young’s Modulus by the 
BV/TV. Value is reported in units of GigaPascals (GPa). 
 Failure Stress (Pfail): This is an estimate of the stress along the y-axis required 
to cause overall failure of the biopsy segment and is calculated by dividing the 
Ultimate Force by the Cross-Sectional Area and multiplying by the Side Artifact 
Correction Factor. Value is reported in units of MegaPascals (MPa). 
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